Quarterly ResultMay 11, 2026, 04:20 PM
Perspective Therapeutics Raises $175M; Q1 Net Loss $(26.2)M
AI Summary
Perspective Therapeutics, Inc. reported a net loss of $(26.2) million for the first quarter of 2026, an increase from $(18.2) million in the same period last year. Despite the increased loss, the company significantly bolstered its financial position by closing an underwritten offering in February 2026, which generated approximately $175.0 million in gross proceeds. As a result, cash, cash equivalents, and short-term investments stood at $270.9 million as of March 31, 2026, which management believes will fund operations into late 2027.
Key Highlights
- Closed an underwritten offering in February 2026, raising $175.0 million in gross proceeds.
- Reported a net loss of $(26.2) million for Q1 2026, compared to $(18.2) million in Q1 2025.
- Basic and diluted loss per share was $(0.25) for both Q1 2026 and Q1 2025.
- Research and development expenses increased to $21.4 million in Q1 2026 from $14.3 million in Q1 2025.
- General and administrative expenses decreased to $7.0 million in Q1 2026 from $7.8 million in Q1 2025.
- Cash, cash equivalents, and short-term investments totaled $270.9 million as of March 31, 2026.
- Total stockholders' equity increased to $347.4 million at March 31, 2026, from $207.0 million at December 31, 2025.
- Operating loss for Q1 2026 was $(28.3) million, up from $(21.8) million in Q1 2025.
Price Impact
More from CATX